ONE FORCE FOWARD
Vertically integrated capabilities for complex life science workflows
Our Story
We are Fortis Life Sciences.
Where Science Finds Momentum.
Fortis was established in 2020 to create a more unified and scalable approach to supporting modern research and development.
Together, Fortis provides capabilities across antibodies, diagnostic components, molecular biology reagents, engineered nanoparticles, and viral vector platforms so you can work with greater continuity across complex scientific workflows.
As a result, work that once required multiple suppliers can move forward with stronger technical alignment, a more stable supply chain, and a partner better equipped to support discovery, translational research, and advanced biologics development.
OCTOBER 2020
Bethyl Labs
For more than 50 years, Bethyl Laboratories has delivered premium-quality antibodies, proteins, and kits manufactured in-house in Montgomery, Texas. Reagents undergo rigorous validation across immunoassays including flow cytometry, spatial biology, and ELISA.
JUNE 2021
nanoComposix
nanoComposix expanded Fortis capabilities in nanomaterial development and production. Highly characterized particles support therapeutics, diagnostics, and applied technologies worldwide.
SEPTEMBER 2021
Empirical Bioscience
Empirical Bioscience added genomic technologies and expanded recombinant protein manufacturing. The portfolio includes enzymes, buffers, master mixes, and molecular biology reagents supporting diagnostic and genomics programs.
DECEMBER 2021
Arista Biologicals
Arista Biologicals strengthened point-of-care and lateral flow diagnostics with highly characterized capture and detector antibodies, antigens, and controls. Integrated assay development and conjugation services reduce supplier risk and shorten development timelines.
FEBRUARY 2022
Abcore
Abcore became a center of excellence for VHH discovery, offering phage display services and AbNano VHH libraries to address difficult and emerging targets across research, therapeutic, and diagnostic programs.
FEBRUARY 2023
IPOC
International Point of Care expanded Fortis lyophilization capabilities for molecular and immunodiagnostic testing. Freeze-dried reagents improve stability, reproducibility, and shelf life for global diagnostic programs.
MARCH 2023
Vector Biolabs
Vector Biolabs strengthened viral vector design and production, offering catalog and end-to-end AAV and adenoviral solutions that accelerate discovery and translational programs.
Proven Scientific Legacies
6
North American manufacturing and R&D locations with three operating under ISO 13485 certification and cGMP standards
1,000+
Biopharma, diagnostics, research, and applied technology customers globally
30,000+
Citations in peer-reviewed scientific publications
75+
Distributors serving customers across 65 countries
